The Lira Pump Trial

Phase 2/3 Completed 44 enrolled Hvidovre University Hospital Steno Diabetes Center Copenhagen · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes patients in suboptimal glycemic control.

Timeline

Start: 2015-02
Primary completion: 2016-10
Completion: 2016-10

Outcome

Met primary endpoint

paper between-group difference 7 mmol/mol [0.7%], P < 0.001 PMID 31696598 ↗

Publications

Results Dejgaard TF, Schmidt S, Frandsen CS, Vistisen D, Madsbad S, Andersen HU, Norgaard K. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial. Diabetes Obes Metab. 2020 Apr;22(4):492-500. doi: 10.1111/dom.13911. Epub 2019 Dec 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	1.8 mg	Subcutaneous